Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments in the United States, Germany, and Canada. The company develops BPL-003, an intranasal formulation of the benzoate salt form of mebufotenin that is in Phase 2a and 2b clinical studies for treatment resistant depression (TRD) and alcohol use disorder; RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia; and ELE-101, a serotonergic psychedelic in Phase 2a trial for the treatment of major depressive disorder. It is also developing VLS-01, an oral transmucosal film formulation of N,N-Dimethyltryptamine in Phase 2 clinical study to treat TRD; EMP-01, an oral formulation of R-3,4-methylenedioxy-methamphetamine that is in Phase 2 clinical study for social anxiety disorder; and EGX-A & EGX-B, which are non-hallucinogenic 5-HT2A receptor agonists in preclinical studies for TRD. In addition, the company offers COMP360 for psilocybin therapy; and GRX-917 for the treatment of anxiety, depression, and various neurological disorders. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany.
Metrics to compare | ATAI | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipATAIPeersSector | |
---|---|---|---|---|
P/E Ratio | −5.3x | −1.2x | −0.5x | |
PEG Ratio | 0.02 | −0.01 | 0.00 | |
Price/Book | 5.2x | 2.0x | 2.6x | |
Price / LTM Sales | 425.9x | 2.5x | 3.2x | |
Upside (Analyst Target) | 157.7% | 159.3% | 40.5% | |
Fair Value Upside | Unlock | 16.3% | 4.4% | Unlock |